Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lipid Disorder Treatment Market

4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Lipid Disorder Treatment Market Analysis and Forecast, 2017–2031

5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry

6. Global Lipid Disorder Treatment Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2017–2031
        6.3.1. Atorvastatin
        6.3.2. Fluvastatin
        6.3.3. Rosuvastatin
        6.3.4. Simvastatin
        6.3.5. Pravastatin
        6.3.6. Other Drugs
    6.4. Market Attractiveness Analysis, by Drug Type

7. Global Lipid Disorder Treatment Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017–2031
        7.3.1. Retail Pharmacies
        7.3.2. Hospital Pharmacies
        7.3.3. Online Pharmacies
    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Lipid Disorder Treatment Market Analysis and Forecast, by Indication
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Indication, 2017–2031
        8.3.1. Familial Combined Hyperlipidemia
        8.3.2. Familial Defective Apolipoprotein B-100
        8.3.3. Familial Dysbetalipoproteinemia
        8.3.4. Familial Hypertriglyceridemia
        8.3.5. Heterozygous Familial Hypercholesterolemia
        8.3.6. Other Indications
    8.4. Market Attractiveness Analysis, by Indication

9. Global Lipid Disorder Treatment Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region

10. North America Lipid Disorder Treatment Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Drug Type, 2017–2031
        10.3.1. Atorvastatin
        10.3.2. Fluvastatin
        10.3.3. Rosuvastatin
        10.3.4. Simvastatin
        10.3.5. Pravastatin
        10.3.6. Other Drugs
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Retail Pharmacies
        10.4.2. Hospital Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Indication, 2017–2031
        10.5.1. Familial Combined Hyperlipidemia
        10.5.2. Familial Defective Apolipoprotein B-100
        10.5.3. Familial Dysbetalipoproteinemia
        10.5.4. Familial Hypertriglyceridemia
        10.5.5. Heterozygous Familial Hypercholesterolemia
        10.5.6. Other Indications
    10.6. Market Value Forecast, by Country, 2017–2031
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Drug Type
        10.7.2. By Distribution Channel
        10.7.3. By Indication
        10.7.4. By Country

11. Europe Lipid Disorder Treatment Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Drug Type, 2017–2031
        11.3.1. Atorvastatin
        11.3.2. Fluvastatin
        11.3.3. Rosuvastatin
        11.3.4. Simvastatin
        11.3.5. Pravastatin
        11.3.6. Other Drugs
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Retail Pharmacies
        11.4.2. Hospital Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Indication, 2017–2031
        11.5.1. Familial Combined Hyperlipidemia
        11.5.2. Familial Defective Apolipoprotein B-100
        11.5.3. Familial Dysbetalipoproteinemia
        11.5.4. Familial Hypertriglyceridemia
        11.5.5. Heterozygous Familial Hypercholesterolemia
        11.5.6. Other Indications
    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Type
        11.7.2. By Distribution Channel
        11.7.3. By Indication
        11.7.4. By Country/Sub-region
12. Asia Pacific Lipid Disorder Treatment Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Drug Type, 2017–2031
        12.3.1. Atorvastatin
        12.3.2. Fluvastatin
        12.3.3. Rosuvastatin
        12.3.4. Simvastatin
        12.3.5. Pravastatin
        12.3.6. Other Drugs
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Retail Pharmacies
        12.4.2. Hospital Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Indication, 2017–2031
        12.5.1. Familial Combined Hyperlipidemia
        12.5.2. Familial Defective Apolipoprotein B-100
        12.5.3. Familial Dysbetalipoproteinemia
        12.5.4. Familial Hypertriglyceridemia
        12.5.5. Heterozygous Familial Hypercholesterolemia
        12.5.6. Other Indications
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Type
        12.7.2. By Distribution Channel
        12.7.3. By Indication
        12.7.4. By Country/Sub-region
13. Latin America Lipid Disorder Treatment Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Drug Type, 2017–2031
        13.3.1. Atorvastatin
        13.3.2. Fluvastatin
        13.3.3. Rosuvastatin
        13.3.4. Simvastatin
        13.3.5. Pravastatin
        13.3.6. Other Drugs
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Retail Pharmacies
        13.4.2. Hospital Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Indication, 2017–2031
        13.5.1. Familial Combined Hyperlipidemia
        13.5.2. Familial Defective Apolipoprotein B-100
        13.5.3. Familial Dysbetalipoproteinemia
        13.5.4. Familial Hypertriglyceridemia
        13.5.5. Heterozygous Familial Hypercholesterolemia
        13.5.6. Other Indications
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Type
        13.7.2. By Distribution Channel
        13.7.3. By Indication
        13.7.4. By Country/Sub-region
14. Middle East & Africa Lipid Disorder Treatment Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Drug Type, 2017–2031
        14.3.1. Atorvastatin
        14.3.2. Fluvastatin
        14.3.3. Rosuvastatin
        14.3.4. Simvastatin
        14.3.5. Pravastatin
        14.3.6. Other Drugs
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Retail Pharmacies
        14.4.2. Hospital Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Indication, 2017–2031
        14.5.1. Familial Combined Hyperlipidemia
        14.5.2. Familial Defective Apolipoprotein B-100
        14.5.3. Familial Dysbetalipoproteinemia
        14.5.4. Familial Hypertriglyceridemia
        14.5.5. Heterozygous Familial Hypercholesterolemia
        14.5.6. Other Indications
    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Type
        14.7.2. By Distribution Channel
        14.7.3. By Indication
        14.7.4. By Country/Sub-region

15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. Pfizer Inc.
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Novartis AG
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. AstraZeneca
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Merck & Co., Inc.
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Emcure Pharmaceuticals Ltd.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Teva Pharmaceuticals Industries Ltd.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Mylan N.V.
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Kowa Pharmaceuticals America, Inc.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Glenmark Pharmaceuticals Ltd.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Sun Pharmaceuticals Industries Ltd.
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
        15.3.11. Wockhardt Limited
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Financial Overview
            15.3.11.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Lipid Disorder Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global Lipid Disorder Treatment Market Revenue (US$ Mn), by Drug Type, 2022

Figure 03: Global Lipid Disorder Treatment Market Value Share, by Drug Type, 2022

Figure 04: Global Lipid Disorder Treatment Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 05: Global Lipid Disorder Treatment Market Value Share, by Distribution Channel, 2022

Figure 06: Global Lipid Disorder Treatment Market Revenue (US$ Mn), by Indication, 2022

Figure 07: Global Lipid Disorder Treatment Market Value Share, by Indication, 2022

Figure 08: Global Lipid Disorder Treatment Market Value Share, by Region, 2022

Figure 09: Global Lipid Disorder Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 11: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 12: Global Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 13: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 14: Global Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031

Figure 15: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2022-2031

Figure 16: Global Lipid Disorder Treatment Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global Lipid Disorder Treatment Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Lipid Disorder Treatment Market Value Share Analysis, by Country, 2022 and 2031

Figure 21: North America Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 22: North America Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 23: North America Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031

Figure 24: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 25: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 26: North America Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023–2031

Figure 27: Europe Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 31: Europe Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 32: Europe Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031

Figure 33: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 34: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 35: Europe Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023–2031

Figure 36: Asia Pacific Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 40: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 41: Asia Pacific Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031

Figure 42: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 43: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 44: Asia Pacific Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023–2031

Figure 45: Latin America Lipid Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 49: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 50: Latin America Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031

Figure 51: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 52: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 53: Latin America Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023–2031

Figure 54: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 58: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 59: Middle East & Africa Lipid Disorder Treatment Market Value Share Analysis, by Indication, 2022 and 2031

Figure 60: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 61: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 62: Middle East & Africa Lipid Disorder Treatment Market Attractiveness Analysis, by Indication, 2023–2031

List of Tables

List of Tables

Table 01: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 04: Global Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 07: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 08: North America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 09: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Europe Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 13: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 15: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 17: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 19: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 20: Latin America Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 21: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 24: Middle East & Africa Lipid Disorder Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2031